Phase 3 clinical studies have confirmed that the gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix significantly reduces pain in women with endometriosis

Myovant Sciences announced that a triennial relugolix combination therapy (Relugolix 40 mg of estradiol 1.0 mg, acetate ketone 0.5 mg) treats pain in women with endometriosis, a phase III study of ENDoscosis 2 reached the primary therapeutic endpoint and six secondary endpointsAnd Relugolix combination therapy is well toleratedRelugolix is a daily oral gonadotropin release hormone (GnRH) receptor antagonist that reduces the production of ovarian lymgenetics, which stimulates the growth of uterine fibroids and endometriosisin spirit 2 results analysis, 75.2% of women who received relugolix combination therapy achieved clinically meaningful improvements in menstruation, compared with 30.4% in the placebo group (p 0.0001)For non-menstrual pelvic pain, 66.0% of women with relugolix combination therapy achieved a meaningful clinical improvement, with a placebo group of 42.6% (p .0001)On average, women who received relugolix combined treatment for relugolix had a 75.1 percent reduction in pain from 7.2 (severe pain) to 1.7 (mild pain), based on a 11-point (0-10) digital score scaleMyovant also announced that in another clinical study, relugolix combined therapy achieved 100% ovulation inhibition in 67 healthy women over an 84-day treatment period, according to the Hoogland-Skouby Assessment ScaleIn addition, 100 per cent of women who have stopped ovulation or menstruation after discontinuation have an average ovulation time of 23.5 daysendometriosis is an inflammatory disease of estrogen dependencePain caused by endometriosis, initial treatment options include hormonal contraceptives and over-the-counter painkillersIn more severe cases, GnRH agonists can be used for short-term treatmentNearly 200 million women worldwide are affected by the disease